trending Market Intelligence /marketintelligence/en/news-insights/trending/dSNLqZgvlSbB-HQ0uCR4HA2 content esgSubNav
In This List

Apellis closes $117.3M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Apellis closes $117.3M common stock offering

Apellis Pharmaceuticals Inc. closed a public offering of 6.9 million common shares priced at $17 each to raise $117.3 million in gross proceeds.

Shares sold include the additional 900,000 stocks underwriters could have bought as part of their overallotment option,

Citigroup, J.P. Morgan and Cowen acted as joint book-running managers for the offering, while Cantor Fitzgerald & Co. acted as lead manager.

Crestwood, Ky.-based Apellis Pharmaceuticals develops therapies for autoimmune and inflammatory diseases.